Cointime update: Grand Pharma’s key nuclear medicine product Yigan Tai (yttrium-90 microsphere injection) was selected for the first time into China’s Commercial Health Insurance Innovative Drug Catalog (2026), issued by the National Healthcare Security Administration, and also into the first edition of the Commercial Health Insurance Drug Recommendation List released by the Insurance Association of China. It is the only selective internal radiation therapy (SIRT) product included in the commercial insurance innovative drug catalog this time.
Grand Pharma’s Y-90 Microsphere Product Added to China Commercial Insurance Drug List
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
7m ago
US Compute-Cloud Stocks Rise in Pre-Market Trading
24m ago
UBS Global Wealth Management Forecasts S&P 500 at 8,200 by End-2027
45m ago
Tencent Q3 2026 Revenue Rises 8% to RMB 207.3 Billion
48m ago
Onshore yuan closes at 6.6653 per dollar, up 2 pips
1h ago
Binance Hot Wallet Attacker Moves 78,415 ETH Worth $142M
1h ago
Hong Kong’s Hang Seng closes down 0.91%; Zhipu jumps over 9%